Cell Reports (Mar 2023)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation

  • Hemn Mohammadpour,
  • Takemasa Tsuji,
  • Cameron R. MacDonald,
  • Joseph L. Sarow,
  • Hanna Rosenheck,
  • Saeed Daneshmandi,
  • Jee Eun Choi,
  • Jingxin Qiu,
  • Junko Matsuzaki,
  • Agnieszka K. Witkiewicz,
  • Kristopher Attwood,
  • Bruce R. Blazar,
  • Kunle Odunsi,
  • Elizabeth A. Repasky,
  • Philip L. McCarthy

Journal volume & issue
Vol. 42, no. 3
p. 112250

Abstract

Read online

Summary: Abundant donor cytotoxic T cells that attack normal host organs remain a major problem for patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). Despite an increase in our knowledge of the pathobiology of acute graft versus host disease (aGvHD), the mechanisms regulating the proliferation and function of donor T cells remain unclear. Here, we show that activated donor T cells express galectin-3 (Gal-3) after allo-HCT. In both major and minor histocompatibility-mismatched models of murine aGvHD, expression of Gal-3 is associated with decreased T cell activation and suppression of the secretion of effector cytokines, including IFN-γ and GM-CSF. Mechanistically, Gal-3 results in activation of NFAT signaling, which can induce T cell exhaustion. Gal-3 overexpression in human T cells prevents severe disease by suppressing cytotoxic T cells in xenogeneic aGvHD models. Together, these data identify the Gal-3-dependent regulatory pathway in donor T cells as a critical component of inflammation in aGvHD.

Keywords